Sangamo Therapeutics, Inc.
SGMO
$0.15
-$0.02-12.73%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.56M | 39.55M | 32.88M | 81.71M | 63.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.56M | 39.55M | 32.88M | 81.71M | 63.76M |
| Cost of Revenue | 113.23M | 112.67M | 104.71M | 104.30M | 101.44M |
| Gross Profit | -78.68M | -73.12M | -71.83M | -22.59M | -37.68M |
| SG&A Expenses | 31.65M | 34.89M | 36.99M | 37.85M | 43.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.88M | 147.56M | 141.70M | 142.15M | 144.46M |
| Operating Income | -110.32M | -108.00M | -108.83M | -60.44M | -80.70M |
| Income Before Tax | -124.02M | -123.50M | -109.35M | -63.50M | -79.60M |
| Income Tax Expenses | -687.00K | -568.00K | -442.00K | -193.00K | -146.00K |
| Earnings from Continuing Operations | -123.33 | -122.93 | -108.91 | -63.31 | -79.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -123.33M | -122.93M | -108.91M | -63.31M | -79.45M |
| EBIT | -110.32M | -108.00M | -108.83M | -60.44M | -80.70M |
| EBITDA | -106.66M | -104.04M | -104.58M | -55.97M | -75.98M |
| EPS Basic | -0.38 | -0.44 | -0.44 | -0.28 | -0.38 |
| Normalized Basic EPS | -0.22 | -0.25 | -0.28 | -0.17 | -0.23 |
| EPS Diluted | -0.38 | -0.44 | -0.45 | -0.29 | -0.39 |
| Normalized Diluted EPS | -0.22 | -0.25 | -0.28 | -0.17 | -0.23 |
| Average Basic Shares Outstanding | 1.29B | 1.12B | 991.67M | 895.75M | 842.75M |
| Average Diluted Shares Outstanding | 1.29B | 1.12B | 991.67M | 901.73M | 848.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |